Cibenzoline improves coronary flow velocity reserve in patients with hypertrophic obstructive cardiomyopathy

Heart and Vessels

Volumn 21, Issue 6, 2006, Pages 350-355

  Sekine, Tai ^a   Daimon, Masao ^a   Hasegawa, Rei ^a   Teramoto, Kiyomi ^a   Kawata, Takayuki ^a   Tanaka, Nobuhiro ^b   Takei, Yasuhiro ^b   Takazawa, Kenji ^b   Yoshida, Katsuya ^a   Komuro, Issei ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Antiarrhythmia agent; Cardiomyopathy; Coronary circulation; Hypertrophic

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTIARRHYTHMIC AGENT; CIBENZOLINE; IMIDAZOLE DERIVATIVE;

AGED; ANALYSIS OF VARIANCE; ARTICLE; BLOOD FLOW VELOCITY; CHEMICALLY INDUCED DISORDER; CORONARY ARTERY BLOOD FLOW; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFECT; ECHOGRAPHY; FEMALE; HEART LEFT VENTRICLE FUNCTION; HEART OUTFLOW TRACT OBSTRUCTION; HUMAN; HYPEREMIA; HYPERTROPHIC CARDIOMYOPATHY; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ADENOSINE TRIPHOSPHATE; AGED; ANALYSIS OF VARIANCE; ANTI-ARRHYTHMIA AGENTS; BLOOD FLOW VELOCITY; CARDIOMYOPATHY, HYPERTROPHIC; CORONARY CIRCULATION; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HUMANS; HYPEREMIA; IMIDAZOLES; MALE; MIDDLE AGED; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT; VENTRICULAR OUTFLOW OBSTRUCTION;

EID: 36049032354     PISSN: 09108327     EISSN: 16152573     Source Type: Journal    
DOI: 10.1007/s00380-006-0917-1     Document Type: Article

References (27)

1. Maron BJ, Bonow RO, Cannon RO III, Leon MB, Epstein SE (1987) Hypertrophic cardiomyopathy: interrelations of clinical manifestation, pathophysiology and therapy (2). N Engl J Med 316: 844-852
2. Maron BJ, Wolfson JK, Epstein SE, Roberts WC (1986) Internal ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol 8: 545-557
3. Cannon RO 3rd, Schenke WH, Maron BJ, Tracy CM, Leon MB, Brush JE Jr, Rosing DR, Epstein SE (1987) Differences in coronary flow and myocardial metabolism at rest and during pacing between patients with obstructive and non-obstructive cardiomyopathy. J Am Coll Cardiol 10: 53-62
4. Jung WI, Sieverding L, Breuer J, Hoess T, Widmaier S, Schmidt O, Bunse M, van Erckelens F, Apitz J, Lutz O, Dietze GJ (1998) 31P NMR spectroscopy detects metabolic abnormalities in asymptomatic patients with hypertrophic cardiomyopathy. Circulation 97: 2536-2542
5. Gould KL, Lipscomb K, Hamilton GW (1974) Physiologic basis for assessing critical coronary stenosis: instantaneous flow response and regional distribution during coronary hyperemia as measures of coronary flow reserve. Am J Cardiol 33: 87-94
6. Lorenzoni R, Gistri R, Cecchi F, Olivotto I, Chiriatti G, Elliott P, McKenna WJ, Camici PG (1998) Coronary vasodilator reserve is impaired in patients with hypertrophic cardiomyopathy and left ventricular dysfunction. Am Heart J 136: 972-981
7. Camici P, Chiriatti G, Lorenzoni R, Bellina RC, Gistri R, Italiani G, Parodi O, Salvadori PA, Nista N, Papi L (1991) Coronary vasodilation is impaired in both hypertrophied and non hypertrophied myocardium of patients with hypertrophic cardiomyopathy: a study with nitrogen-13 ammonia and positron emission tomography. J Am Coll Cardiol 17: 879-886
8. Cannon RO 3rd, Rosing DR, Maron BJ, Leon MB, Bonow RO, Watson RM, Epstein SE (1985) Myocardial ischemia in patients with hypertrophic cardiomyopathy: contribution of inadequate vasodilator reserve and elevated left ventricular filling pressures. Circulation 71: 234-243
9. Kyriakidis MK, Dernellis JM, Androulakis AE, Kelepeshis GA, Barbetseas J, Anastasakis AN, Trikas AG, Tentolouris CA, Gialafos JE, Toutouzas PK (1997) Changes in phasic coronary blood flow velocity profile and relative coronary flow reserve in patients with hypertrophic obstructive cardiomyopathy. Circulation 96: 834-841
10. Hongo M, Nakatsuka T, Takenaka H, Tanaka M, Watanabe N, Yazaki Y, Sekiguchi M (1996) Effects of intravenous disopyramide on coronary hemodynamics and vasodilator reserve in hypertrophic obstructive cardiomyopathy. Cardiology 87: 6-11
11. Krams R, Kofflard MJ, Duncker DJ, Von Birgelen C, Carlier S, Kliffen M, ten Cate FJ, Serruys PW (1998) Decreased coronary flow reserve in hypertrophic cardiomyopathy is related to remodeling of the coronary microcirculation. Circulation 97: 230-233
12. Schwartzkopff B, Mundhenke M, Strauer BE (1998) Alterations of the architecture of subendocardial arterioles in patients with hypertrophic cardiomyopathy and impaired coronary vasodilator reserve: a possible cause for myocardial ischemia. J Am Coll Cardiol 31: 1089-1096
13. Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici PG (2003) Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 349: 1027-1035
14. Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, Cecchi F, Maron BJ (2003) Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 348: 295-303
15. Hamada M, Shigematsu Y, Ikeda S, Hara Y, Okayama H, Kodama K, Ochi T, Hiwada K (1997) Class Ia antiarrhythmic drug cibenzoline: a new approach to the medical treatment of hypertrophic obstructive cardiomyopathy. Circulation 96: 1520-1524
16. Hozumi T, Yoshida K, Akasaka T, Asami Y, Ogata Y, Takagi T, Kaji S, Kawamoto T, Ueda Y, Morioka S (1998) Noninvasive assessment of coronary flow velocity and coronary flow velocity reserve in the left anterior descending coronary artery by Doppler echocardiography - comparison with invasive technique. J Am Coll Cardiol 32: 1251-1259
17. Daimon M, Watanabe H, Yamagishi H, Muro T, Akioka K, Hirata K, Takeuchi K, Yoshikawa J (2001) Physiologic assessment of coronary artery stenosis by coronary flow reserve measurements with transthoracic Doppler echocardiography: comparison with exercise thallium-201 single-photon emission computed tomography. J Am Coll Cardiol 37: 1310-1315
18. Hirata K, Amudha K, Elina R, Hozumi T, Yoshikawa J, Homma S, Lang CC (2004) Measurement of coronary vasomotor function: getting to the heart of the matter in cardiovascular research. Clin Sci (Lond) 107: 449-460
19. Brazzell RK, Khoo KC, Szuna AJ, Sandor D, Aogaichi K, Wills RJ (1985) Pharmacokinetics and pharmacodynamics of intravenous cibenzoline in normal volunteers. J Clin Pharmacol 25: 418-423
20. Bryg RJ, Pearson AC, Williams GA, Labovitz AJ (1987) Left ventricular systolic and diastolic flow abnormalities determined by Doppler echocardiography in obstructive hypertrophic cardiomyopathy. Am J Cardiol 59: 925-931
21. Hamada M, Shigematsu Y, Hara Y, Suzuki M, Ohtsuka T, Hiasa G, Ogimoto A, Saeki H, Suzuki J, Hiwada K (2001) Antiarrhythmic drug, cibenzoline, can directly improve the left ventricular diastolic function in patients with hypertrophic cardiomyopathy. Jpn Circ J 65: 531-538
22. Miller JS, Vaughan William EM (1982) Effect on rabbit nodal, atrial, ventricular and Purkinje cell potentials of a new antiarrhythmic drug, cibenzoline, which protects against action potential shortening in hypoxia. Br J Pharmacol 75: 469-478
23. Holck M, Osterieder W (1986) Inhibition of the myocardial Ca2+ inward current by the class I antiarrhythmic agent, cibenzoline. Br J Pharmacol 87: 705-711
24. Pollick C (1982) Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide. N Engl J Med 307: 997-999
25. Sumimoto T, Hamada M, Ohtani T, Suzuki M, Abe M, Matsuoka H, Fujiwara Y, Sekiya M, Hiwada K (1992) Effect of disopyramide on left ventricular diastolic function in patients with hypertrophic cardiomyopathy: comparison with diltiazem. Cardiovasc Drugs Ther 6: 425-428
26. Cannon RO 3rd, Dilsizian V, O'Gara PT, Udelson JE, Schenke WH, Ouyyumi A, Fananapazir L, Bonow RO (1991) Myocardial metabolic hemodynamic and electrocardiographic significance of reversible thallium-201 abnormalities in hypertrophic cardiomyopathy. Circulation 83: 1660-1667
27. Rajappan K, Rimoldi OE, Camici PG, Bellenger NG, Pennell DJ, Sheridan DJ (2003) Functional changes in coronary microcirculation after valve replacement in patients with aortic stenosis. Circulation 107: 3170-3175